Showing results (61-70 of 76) with videos related to

Sort By:
Pageof 8
Clinical Lung Cancer|August 14, 2021
Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD)Helena A Yu, Sarah B Goldberg, Xiuning Le, et al.
Lung Cancer (Amsterdam, Netherlands)|June 26, 2026
Durvalumab plus etoposide-platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and neuroendocrine transformation after first-line osimertinib: ORCHARDIsamu Okamoto, Byoung Chul Cho, Sarah B Goldberg, et al.
Lung Cancer (Amsterdam, Netherlands)|July 1, 2022
High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from the phase 2 multicenter POSITION20 trialFenneke Zwierenga, Bianca van Veggel, Lizza E L Hendriks, et al.
Lung Cancer (Amsterdam, Netherlands)|June 29, 2015
Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysisJustine L Kuiper, Lizza E Hendriks, Anthonie J van der Wekken, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2017
Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma PatientsDennis Plenker, Miriam Bertrand, Adrianus J de Langen, et al.
JTO Clinical and Research Reports|August 12, 2025
Longitudinal Circulating Tumor DNA-Guided Resistance Analysis During Second-Line Osimertinib TreatmentJ W Tijmen van der Wel, Merel Jebbink, Vincent van der Noort, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|June 4, 2023
Blood platelet RNA profiles do not enable for nivolumab response prediction at baseline in patients with non-small cell lung cancerMirte Muller, Myron G Best, Vincent van der Noort, et al.
The Journal of Pathology|July 6, 2022
Feasibility of whole-genome sequencing-based tumor diagnostics in routine pathology practiceKris G Samsom, Luuk J Schipper, Paul Roepman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2024
Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non-Small Cell Lung Cancer-Results from the Drug Rediscovery ProtocolKarlijn Verkerk, Tijmen J W T van der Wel, Laurien J Zeverijn, et al.
Frontiers in Oncology|March 27, 2023
Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC)Marinda Meertens, M Benthe Muntinghe-Wagenaar, Barend J Sikkema, et al.
Pageof 8